In-Vivo Evaluation Of Carvedilol-?ÄÔÇÖ-Cyclodextrin Inclusion Complexes
Main Article Content
Abstract
ABSTRACT
Carvedilol (BCS Class II drug) is a nonselective ?Ä??-adrenergic blocking agent with ?Ä??1-blocking activity having poor oral bioavailability. The objective of this study is to enhance the oral bioavailability of carvedilol. To improve oral bioavailability of carvedilol, carvedilol ?Ä??-Cyclodextrin complex were formulated by employing the kneading method with the drug: complexing agent1:2. The complexes and pure drug were subjected to pharmacokinetic studies in rabbits. The plasma samples were analyzed by LC-MS/MS method. Various pharmacokinetic parameters were calculated. Carvedilol ?Ä??-Cyclodextrin complex showed higher Ka, AUC values compared with pure drug. Carvedilol ?Ä??-Cyclodextrin complex showed 1.78 fold increases in extent of absorption.
Carvedilol (BCS Class II drug) is a nonselective ?Ä??-adrenergic blocking agent with ?Ä??1-blocking activity having poor oral bioavailability. The objective of this study is to enhance the oral bioavailability of carvedilol. To improve oral bioavailability of carvedilol, carvedilol ?Ä??-Cyclodextrin complex were formulated by employing the kneading method with the drug: complexing agent1:2. The complexes and pure drug were subjected to pharmacokinetic studies in rabbits. The plasma samples were analyzed by LC-MS/MS method. Various pharmacokinetic parameters were calculated. Carvedilol ?Ä??-Cyclodextrin complex showed higher Ka, AUC values compared with pure drug. Carvedilol ?Ä??-Cyclodextrin complex showed 1.78 fold increases in extent of absorption.
Downloads
Download data is not yet available.
Article Details
Section
Research Articles
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.